Loading the comparison…
Loading the comparison…
Sexual Health
Works through the brain, not blood flow — and it's FDA-approved for women.
Women's Health
A non‑hormonal peptide aimed at disease‑modifying treatment for endometriosis.
PT-141 is approved in another form or use and rated 4/5 for evidence; ENDO-205 is not FDA-approved and rated 2/5. PT-141 has more human evidence behind it. PT-141 is listed under Sexual Health; ENDO-205 under Women's Health.
| Compare | PT-141 Works through the brain, not blood flow — and it's FDA-approved for women. | ENDO-205 A non‑hormonal peptide aimed at disease‑modifying treatment for endometriosis. |
|---|---|---|
| Category | Sexual Health | Women's Health |
| Evidence | 4/5Phase 3 RCTs in women (RECONNECT) led to FDA approval; men's data is smaller. | 2/5Preclinical (animal) studies have shown lesion reduction; no human efficacy data yet. |
| FDA status | Approved (narrow indication): Vyleesi (2019), HSDD in premenopausal women only | IND cleared; not FDA‑approved |
| WADA (sport) | Not on the Prohibited List | Not on the Prohibited List |
| Also known as | Bremelanotide, Vyleesi | – |
| How it works | Melanocortin-4 receptor agonist in the hypothalamus; acts on desire pathways rather than vascular function. | The peptide is designed to bind a downstream component of a pathway that drives endometriosis lesion migration and invasion, and is reported to be absorbed primarily in endometriosis tissue. |
| Half-life | About 2–3 hours | Unknown |
| Commonly reported doses |
| |
| Route | Subcutaneous (abdomen/thigh) | – |
| Good once mixed | ~28 days in the fridge | No published dose yet |
| Top side effects |
| |
| Lowest research-listing price per mg | $1.80 (10 mg vial, 40% off) | – |
| Latest lab purity | 99.91% (lot PT0002) | – |
Want a third? Add another peptide. Doses are commonly reported ranges, not recommendations.
Free for ChatGPT and Claude
Connect MyPeps to ChatGPT or Claude and ask follow-ups about PT-141 and ENDO-205. It answers from these same pages, with links back here.
PT-141 is approved in another form or use and rated 4/5 for evidence; ENDO-205 is not FDA-approved and rated 2/5. PT-141 has more human evidence behind it. PT-141 is listed under Sexual Health; ENDO-205 under Women's Health.
PT-141: Approved (narrow indication): Vyleesi (2019), HSDD in premenopausal women only. ENDO-205: IND cleared; not FDA‑approved. Regulations change, so confirm with the FDA.
PT-141 is rated 4 out of 5: Phase 3 RCTs in women (RECONNECT) led to FDA approval; men's data is smaller. ENDO-205 is rated 2 out of 5: Preclinical (animal) studies have shown lesion reduction; no human efficacy data yet. The scale is explained on our methodology page.
PT-141 is not named on the WADA list, though the general rule on non-approved substances (S0) can still apply. ENDO-205 is not named on the WADA list, though the general rule on non-approved substances (S0) can still apply.